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ABSTRACT
Objective: To determine the long-term effectiveness
of a complex intervention in primary care aimed at
improving outcomes for patients with coronary heart
disease.
Design: A 6-year follow-up of a cluster randomised
controlled trial, which found after 18 months that
both total and cardiovascular hospital admissions
were significantly reduced in intervention practices
(8% absolute reduction).
Setting: 48 general practices in the Republic of
Ireland and Northern Ireland.
Participants: 903 patients with established coronary
heart disease at baseline in the original trial.
Intervention: The original intervention consisted of
tailored practice and patient plans; training sessions for
practitioners in medication prescribing and behavioural
change; and regular patient recall system. Control
practices provided usual care. Following the
intervention period, all supports from the research
team to intervention practices ceased.
Outcome measures: Primary outcome: hospital
admissions, all cause and cardiovascular; secondary
outcomes: mortality; blood pressure and cholesterol
control.
Results: At 6-year follow-up, data were collected from
practice records of 696 patients (77%). For those who
had died, we censored their data at the point of death
and cause of death was established. There were no
significant differences between the intervention and
control practices in either total (OR 0.83 (95% CI 0.54
to 1.28)) or cardiovascular hospital admissions (OR
0.91 (95% CI 0.49 to 1.65)). We confirmed mortality
status of 886 of the original 903 patients (98%). There
were no significant differences in mortality (15% in
intervention and 16% in control) or in the proportions
of patients above target control for systolic blood
pressure or total cholesterol.
Conclusions: Initial significant differences in the
numbers of total and cardiovascular hospital
admissions were not maintained at 6 years and no
differences were found in mortality or blood pressure
and cholesterol control. Policymakers need to continue
to assess the effectiveness of previously efficacious
programmes.
Trial registration number: Current Controlled Trials
ISRCTN24081411.
INTRODUCTION
Secondary prevention of coronary heart
disease (CHD), which aims to prevent acute
coronary events and optimise well-being
among those with established CHD, is widely
advocated and promoted. Secondary preven-
tion is multifaceted, including pharmaceut-
ical interventions to manage blood pressure
and cholesterol and interventions to change
behaviour and lifestyle. Health systems in
developed countries now invest considerable,
and recurrent, resources in cardiac second-
ary prevention.
General practice plays an important role in
secondary prevention. Two systematic reviews
of cardiac secondary prevention programmes
have demonstrated improved process (eg,
cholesterol management) and outcome (eg,
mortality).1 2 However, both noted that there
was some evidence of a ‘ceiling effect’
whereby interventions have a diminishing
beneﬁcial effect once certain levels of risk
marker management are reached. Clark et al2
and McAlister et al3 also recommended a
rigorous evaluation of long-term clinical and
economic outcomes.
Strengths and limitations of this study
▪ Strengths include the original study design, the
sample size and the length of follow-up.
▪ The significant differences in the numbers of
total and cardiovascular hospital admissions
observed at the end of the initial intervention
period were not maintained at 6 years, pointing
to a need for research into the potential benefit
of delivering previously efficacious interventions
intermittently over time, based on regular
assessments of incentive effects.
▪ The main limitation to this study is that common
to all trial follow-up studies: crossover between
the intervention and control practices, in terms
of the management of secondary prevention,
could have occurred on study cessation at
18 months.
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An important contributor to the ﬁrst review was our
own SPHERE cluster randomised controlled trial. We
found that a complex 18-month intervention with tai-
lored plans for general practices and patients, which
aimed to improve outcomes for patients with CHD,
resulted in signiﬁcantly reduced hospital admissions but
showed no other beneﬁts, possibly because of a ceiling
effect. The current follow-up study is intended to con-
tribute to an ongoing systematic review of long-term
follow-up studies of primary care organisational interven-
tions for the secondary prevention of ischaemic heart
disease.4
We now report follow-up of the SPHERE participants
after 6 years to ﬁrst determine if the positive impact of
our 18-month intervention on hospital admissions for
patients with established CHD persisted and, second, to
determine the long-term impact on mortality and on
blood pressure and cholesterol control.
METHODS
We reported full details of recruitment, randomisation
and the intervention previously.5 Brieﬂy, in 2004–2005,
we recruited 48 randomly selected general practices in
the Republic of Ireland and Northern Ireland. In each
practice, patients with established CHD, determined by
documented myocardial infarction, coronary artery
bypass grafting, angioplasty or angina (conﬁrmed by
exercise stress test, isotope test or coronary angiogram),
were identiﬁed. Patients with a major mental or physical
illness that would impair their ability to take part in the
intervention (as determined by the general practitioner
(GP)) were excluded. Randomly selected eligible
patients were invited to participate and were asked to
return study postal questionnaires. Following baseline
data collection, practices were randomised to interven-
tion and control by an individual independent of the
research team.
INTERVENTION
The intervention consisted of: (1) tailored practice plans
(action plans for practices were developed and reviewed;
practices received a regular SPHERE study newsletter);
(2) two training sessions for practitioners in medication
prescribing and behavioural change; (3) tailored patient
care plans (patient information booklet provided;
patients identiﬁed one aspect of secondary prevention
to focus on; goals and action plans developed; progress
reviewed) and (4) regular patient recall system estab-
lished where patients were invited to consult with the
GP or practice nurse every 4 months. The intervention
was developed on the basis of a review of the literature
and psychological theory, mainly social cognitive theory,
and modelled following qualitative research and pilot-
ing.6 Control practices continued with usual care5 and,
following the intervention period, all supports from the
research team to intervention practices ceased.
FOLLOW-UP
In 2012, 6 years after randomisation, we traced the ori-
ginal participants through their general practices and
obtained their consent to collect data from their practice
records. For those who had moved practice within
Ireland, we made every attempt to follow them to their
new practices. Patients who moved abroad were lost to
follow-up.
From the practice records, research nurses collected
data on risk factors, medication prescribing, hospital
admissions and length of stay and on coronary events
and procedures. Owing to resource limitations, only
four of the ﬁve research nurses were blinded to the
group allocation. Blood pressure and cholesterol data
recorded in the practice records within 12 months of
the end of the follow-up period were accepted.
For those who had died, we censored their data at the
point of death and obtained conﬁrmation of the cause
of death from the General Registry Ofﬁce (Republic of
Ireland) or from the practice records (Northern
Ireland). This study was approved by the Irish College of
General Practitioners and the Ofﬁce of the Research
Ethics Committees Northern Ireland.
OUTCOME MEASURES
The primary outcome measure was hospital admissions
from practice records. These were calculated for both all
cause and cardiovascular related. An admission was
attributed to a cardiovascular cause only if a cardiovascu-
lar diagnosis or procedure was stated as a primary reason
for an admission. Secondary outcomes included mortal-
ity and blood pressure and cholesterol control. Mortality
was also calculated for both all cause and cardiovascular
related. A death was attributed to a cardiac cause only
if the primary cause of death was cardiac. Lack of
control was deﬁned as follows: systolic blood pressure
>140 mm Hg, diastolic blood pressure >90 mm Hg and
cholesterol level >5.0 mmol/L.
SAMPLE SIZE
Detailed sample size calculations for the original trial
are described elsewhere.7 We achieved the original
intended sample size.
STATISTICAL ANALYSIS
The design employed was that of a longitudinal cluster
randomised trial with inpatient hospital admissions, a
count variable, as the primary response.
Initially, a Poisson regression model was used. Since
many participants had no admissions in a given time
period, two approaches were then used to adjust for
overdispersion: a zero inﬂated Poisson regression model
and a Hurdle model. All models incorporated random
effects for clustering in the data due to randomisation
by general practice and for the correlation due to the
repeated measurements for each individual across time.
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The Hurdle model8 splits the problem into two parts:
initially, the presence and absence of admissions are
modelled using a logistic component and then the
mean count, for those with at least one admission, is
modelled using a (truncated) Poisson regression.
Therefore, whether a hospital admission occurs is con-
sidered ﬁrst, followed by then describing the mean
number of admissions observed. We only report the
results of the logistic component of the Hurdle model
in this paper; the zero inﬂated Poisson regression gave
similar conclusions (data available from authors). There
were no baseline data on cardiovascular admissions, so
the total hospital admissions were used as a proxy
based on the assumption that the proportion of cardio-
vascular and non-cardiovascular admissions was the
same in the intervention and control groups before
baseline.
Linear and non-linear mixed models, which accounted
for missing values, were used to model the variability in
continuous (eg, blood pressure) and categorical (eg,
proportions outside secondary prevention guidelines)
responses, using prespeciﬁed variables (GP cluster, base-
line response, practice size, practice location, age,
gender, years since diagnosis and conditions at baseline:
angina, MI, CABG, PTCA and diabetes). The log rank
test was used to compare survival distributions. All
analyses were carried out using R (2.15), using the nlme,
lme4, glmmADMB, ggplot2 and survival libraries.
RESULTS
Table 1 shows that characteristics of the 48 practices and
the 903 participants enrolled in the original SPHERE
study were well balanced at baseline, apart from occupa-
tional status and educational level.
Figure 1 shows the ﬂow of practices and patients
through the study. For everyone alive at 6 years,
follow-up was exactly 6 years from baseline. No practices
were lost to follow-up. Data were collected from the prac-
tice records of 696 patients, 339 (76%) in the interven-
tion group and 357 (78%) in the control group. It was
not possible to collect follow-up practice record data for
207 patients: in total, 68 did not respond to the invita-
tion to participate, 31 declined to participate, 78 were
not contactable and 30 died during the original inter-
vention period—all equally divided across arms. Of the
original 903 patients, mortality status was conﬁrmed for
886 (435+451 (98%)).
HOSPITAL ADMISSIONS
There were a large number of patients with no admis-
sions in any given time period (70–84%). Table 2 shows
Table 1 Characteristics of the practices and patients at baseline
Characteristic Intervention number (%) Control number (%)
Practice factors
Number of practices 24 24
Practice size
<2 whole time equivalents 9 (47) 10 (53)
≥2 whole time equivalents 15 (52) 14 (48)
Region
Northern Ireland 8 (33) 8 (33)
Republic of Ireland 16 (67) 16 (67)
Patient factors
Number of patients 444 459
Men 312 (70) 321 (70)
Mean (SD) age (years) 68.5 (9.3) 66.5 (9.9)
Mean (SD) years since diagnosis 8.3 (6.6) 8.2 (6.5)
Myocardial infarction 220 (50) 233 (51)
Angina 390 (88) 414 (90)
Diabetes 78 (17.6) 82 (17.9)
Coronary artery bypass grafting 114 (25.7) 124 (27.1)
PTCA 126 (28.4) 149 (32.6)
Eligible for General Medical Scheme* 234 (82.4) 218 (73.4)
Married 288 (67) 315 (70)
Manual occupation† 134 (42) 172 (51)
Completed secondary education† 179 (42) 145 (33)
Physiological variables
Mean (SD) systolic blood pressure (mm Hg) 136.2 (22.2) 136.8 (21.2)
Mean (SD) diastolic blood pressure (mm Hg) 78.4 (12.0) 79.5 (11.3)
Mean (SD) total cholesterol (mmol/L) 4.40 (0.90) 4.34 (0.92)
*Republic of Ireland only. Primary healthcare is free through the General Medical Services scheme only to those judged less able to pay for
such services—approximately one-third of the Irish population.
†Variables prespecified as covariates in the analysis.
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the mean number of all-cause admissions and table 3
shows the mean number of cardiovascular hospital
admissions for all patients across all time points.
Admission counts were converted to annualised values
when applying the linear mixed models, to make the
responses equivalent measures. The results from the
logistic component of the Hurdle model (table 4) show
that, for both all-cause and cardiovascular admissions,
the signiﬁcant differences found in the original
SPHERE study at 18 months persist in the 12-month
equivalent analysed here, but are not apparent at 24, 36,
48, 60 or 72 months.
MORTALITY
There was no evidence that total or cardiac mortality at
6-year follow-up differed between the intervention and
control groups, with 15% deceased in the intervention
group and 16% in the control group (χ2 test, p=0.83)
(table 5). There was no difference in survival functions
between the two groups (Log Rank test, p=0.68).
BLOOD PRESSURE AND TOTAL CHOLESTEROL CONTROL
Table 6 shows the percentage of participants outside
appropriate secondary prevention risk marker guidelines
Figure 1 Flow of practices and patients through the 6-year study period. No response: participants to whom an invitation to take
part in the follow-up study was sent but who did not respond. Uncontactable: participants who were not invited, for a variety of
reasons, to take part in the follow-up, for example, the GP advised not to contact due to severe illness, onset of dementia, family
bereavement or where a participant moved general practice and contact details were no longer available.
Table 2 Mean number of all-cause hospital admissions
at each time point
Intervention Control
Time point N Mean SD N Mean SD
Baseline 440 0.30 0.59 452 0.44 0.77
18 months* 425 0.38 0.74 444 0.55 0.98
2 years* 335 0.17 0.49 357 0.22 0.54
3 years 329 0.33 0.79 352 0.39 0.84
4 years 322 0.36 0.79 341 0.40 0.79
5 years 317 0.39 0.77 335 0.35 0.72
6 years 312 0.30 0.73 330 0.37 0.82
*The first time period is 18 months, followed by a 6-month time
period, with all others on a yearly basis.
Table 3 Mean number of cardiovascular hospital
admissions at each time point
Time point
Intervention Control
N Mean SD N Mean SD
18 months* 425 0.14 0.51 444 0.23 0.70
2 years* 335 0.06 0.27 357 0.07 0.35
3 years 329 0.10 0.36 352 0.12 0.41
4 years 323 0.10 0.35 341 0.13 0.38
5 years 316 0.15 0.44 335 0.11 0.37
6 years 313 0.09 0.35 330 0.11 0.39
*The first time period is 18 months, followed by a 6-month time
period, with all others on a yearly basis. There were no baseline
data on cardiovascular admissions, so the total hospital
admissions were used as a proxy in all models.
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at baseline and at 18 months and 6 years. The propor-
tion of patients outside of the recommended guidelines
decreased from baseline to 6-year follow-up, but the dif-
ferences between groups were not signiﬁcant.
DISCUSSION
We found that after 6 years of follow-up of patients with
established heart disease randomised to a complex inter-
vention with tailored plans for general practices and
patients or usual care, initial signiﬁcant differences at
18 months in the numbers of all-cause and cardiovascu-
lar hospital admissions were not maintained. At the
6-year follow-up, there were also no differences in mor-
tality or blood pressure and cholesterol control.
Three other equivalent studies have reported similar
follow-up periods: Cupples in Belfast,9 Murchie in north
east Scotland10 and Munoz in Catalonia.11 None
reported similar admission data. Murchie reported sig-
niﬁcantly lower cumulative death rates, in favour of inter-
vention practices, of 14.5% and 18.9% (p=0.038).
Cupples reported similar proportions; Munoz found no
signiﬁcant differences in mortality. We are currently con-
ducting a systematic review of all follow-up studies of
cardiac secondary prevention programmes in general
practice.4 The Belfast and Scottish studies were initially
conducted in the early and mid-1990s, respectively, when
control of cardiovascular risk markers for patients with
established heart disease was poorer than it is now. For
example, the mean baseline cholesterol was 6.2 mmol/L
in Belfast, while the mean Scottish baseline cholesterol
was 6.5 mmol/L. These are much higher than what we
found at baseline in 2005 (table 1), which in turn are
similar to those found by Munoz et al12 in 2001.
IMPLICATIONS FOR PRACTICE AND RESEARCH
As suggested by the two systematic reviews,1 2 it may be
that with improved secondary cardiac risk proﬁles for
both individuals and the general population, a ceiling
has now been reached. Gains previously possible in risk
marker management may no longer be attainable.
Table 6 highlights the importance of control groups as
the cholesterol and blood pressure control improved gen-
erally over time. Policymakers need to continue to assess
the effectiveness of previously efﬁcacious programmes.
From an economic perspective, the additional cost of
delivering the intervention for 18 months was offset by
the savings generated from reduced hospital admissions,
leading to an overall reduction in healthcare costs relative
to control at 18 months with no impact on patient health
status.13 Ongoing analysis for our upcoming paper on the
cost-effectiveness of the SPHERE intervention at 6 years
will provide further insight on this question.
The ongoing effects of incentivising or supporting
interventions need to be balanced with a consideration
of the opportunity costs for such incentives. Behavioural
research has conﬁrmed that the impact of a behavioural
intervention diminishes once the intervention
ceases.14 15 Research is needed into the potential beneﬁt
of intermittent incentives or support for interventions
using some sort of ‘turn on, turn off’ approach based on
regular assessments of programme or incentive effects.
LIMITATIONS
The main limitation to this study is that common to all
trial follow-up studies: crossover between the interven-
tion and control practices, in terms of the management
of secondary prevention, could have occurred on study
Table 4 OR of an admission and a cardiovascular admission in the intervention and control groups during follow-up, using
the logistic component of a Hurdle model
Follow-up
(months)
OR for hospital
admissions (intervention
vs control)* 95% CI p Value
OR for CV hospital
admissions (intervention
vs control)* 95% CI p Value
12† 0.65 0.46 to 0.92 0.01 0.62 0.39 to 0.98 0.04
24† 0.64 0.39 to 1.04 0.07 0.89 0.43 to 1.83 0.76
36 0.74 0.49 to 1.12 0.16 0.89 0.51 to 1.56 0.69
48 0.87 0.58 to 1.31 0.51 0.74 0.43 to 1.29 0.29
60 1.19 0.79 to 1.80 0.40 1.39 0.81 to 2.40 0.23
72 0.83 0.54 to 1.28 0.40 0.91 0.49 to 1.65 0.75
*OR adjusted for GP cluster, baseline inpatient admissions, practice size, practice location, age, gender, years since diagnosis and conditions
at baseline: angina, MI, CABG, PTCA and diabetes.
†Data were originally collected at the end of the 18-month intervention and the first follow-up period was 6 months, so these are based on
annualised equivalents of the admission counts.
GP, general practitioner.
Table 5 Total and cardiac mortality at 6 years
Alive, n (%) Deceased, n (%) Cardiac cause of death, n (%)* Not established, n (%)
Intervention 370 (83) 65 (15) 29 (45) 9 (2)
Control 378 (82) 73 (16) 32 (44) 8 (2)
*Of those who died in that study group.
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cessation at 18 months. We simply do not know whether
intervention practices ceased to provide the interven-
tion, or control practices introduced similar approaches,
or a mixture of both. This potentially could result in a
signiﬁcant difference being missed at the follow-up
point and a type II error. The trends over time in tables
4 and 6 do not suggest this. Classiﬁcation of admissions
into cardiovascular or not was dependent on routine
admission records.
We suggest that it would be helpful if there were
general guidelines on how best to report long-term
follow-up studies of trials.
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